REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
20/10/2025
Voltar para busca
Dado oficial do USPTO
SIGILON THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SIGILON THERAPEUTICS
ST13
US500000087508764Classe
1, 5, 10
Pedido
87508764
Registro
6180506
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
59
Atualização mais recente
22/10/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10
Data de depósito
28/06/2017
Data de registro
20/10/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/10/2020
Última transação
22/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
30/01/2018
Primeiro uso no comércio
30/01/2018
Código do desenho
4
Tipo de titular
03
Localização do titular
Cambridge, MA
Examinador
MESSICK,TABITHA LEE
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sigilon Therapeutics, Inc.
Representantes
John R. Rudolph Eli Lilly and Company
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical agents for scientific and research usesmall molecules in the nature of chemical preparations for research and scientific use in the field of cellular therapeutics; reagents for research purposes; reagents for scientific or medical research use
Classe 5
Chemicalpharmaceuticalbiopharmaceutical and biomedical agents for medical useagents for medical usein the nature of agents which mitigate the foreign body response; chemical agents for pharmaceutical or medical purposesagents that mitigate the foreign body response; pharmaceutical agents for encapsulating transplanted cells to prevent the risk of rejection from immune attackfor medical purposes; pharmaceutical preparations for the prevention and treatment of fibrosisinflammationcancer and infection; drug delivery agents in the form of coatings for capsules that facilitate the tolerance and delivery of pharmaceutical preparations; chemical agentsdrug delivery agents for encapsulating pharmaceutical agents and cells that facilitate the delivery of a wide range of pharmaceuticals
Classe 10
Implants consisting of artificial materials; coatings sold as an integral component of implantable medical devices
Publicações
Histórico de despachos e eventos da marca no USPTO.
59 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/03/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/03/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/03/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/03/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
18/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
20/10/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/09/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/09/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/09/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/09/2020
IUAF
USE AMENDMENT FILED
21/08/2020
EISU
TEAS STATEMENT OF USE RECEIVED
21/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/05/2020
EX3G
SOU EXTENSION 3 GRANTED
20/05/2020
EXT3
SOU EXTENSION 3 FILED
20/05/2020
EEXT
SOU TEAS EXTENSION RECEIVED
20/05/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24/12/2019
EX2G
SOU EXTENSION 2 GRANTED
20/12/2019
EXT2
SOU EXTENSION 2 FILED
20/12/2019
EEXT
SOU TEAS EXTENSION RECEIVED
20/12/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28/06/2019
EX1G
SOU EXTENSION 1 GRANTED
26/06/2019
EXT1
SOU EXTENSION 1 FILED
26/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
26/06/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/01/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/12/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/12/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/11/2018
PUBO
PUBLISHED FOR OPPOSITION
06/11/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/10/2018
ALIE
ASSIGNED TO LIE
25/09/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/09/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/09/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/09/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/09/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/09/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/09/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
22/03/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
22/03/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/03/2018
GNRT
NON-FINAL ACTION E-MAILED
07/03/2018
CNRT
NON-FINAL ACTION WRITTEN
07/03/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
14/02/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/02/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
14/02/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/02/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/01/2018
GNRT
NON-FINAL ACTION E-MAILED
11/01/2018
CNRT
NON-FINAL ACTION WRITTEN
11/01/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/12/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/10/2017
GNRT
NON-FINAL ACTION E-MAILED
02/10/2017
CNRT
NON-FINAL ACTION WRITTEN
02/10/2017
DOCK
ASSIGNED TO EXAMINER
26/09/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/07/2017
NWAP
NEW APPLICATION ENTERED
01/07/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SIGILON THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.